Search Patents
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
    Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • MEDICAMENT AND FOOD FOR PREVENTING OR TREATING NOVEL CORONAVIRUS PNEUMONIA COVID-19 AND USE THEREOF
    Publication number: 20220305092
    Abstract: The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.
    Type: Application
    Filed: May 9, 2020
    Publication date: September 29, 2022
    Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD
    Inventors: Mingjie SUN, Tianyu SUN, Changqing LI
  • METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230293521
    Abstract: Disclosed are methods for screening for therapeutic agents that can inhibit a coronavirus infection and methods of using agents identified by said assays to treat a coronavirus infection.
    Type: Application
    Filed: July 14, 2021
    Publication date: September 21, 2023
    Inventors: Christopher Francis Basler, Jesus Silvas, Alexander Jureka
  • Nucleic Acid Compounds That Bind Coronavirus Proteins
    Publication number: 20240218374
    Abstract: Described herein are aptamers capable of binding to coronavirus protein(s); compositions comprising a coronavirus protein binding aptamer with a coronavirus protein; and methods of making and using the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 4, 2024
    Applicant: Somalogic Operating Co., Inc.
    Inventors: Amy D. Gelinas, Daniel J. Schneider, Nebojsa Janjic
  • Prefusion coronavirus spike proteins and their use
    Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • CORONAVIRUS VACCINES
    Publication number: 20240285751
    Abstract: Designed coronavirus polypeptide sequences are described, and their use as vaccines against viruses of the coronavirus family. The designed sequences include designed coronavirus spike (S) proteins and fragments thereof, including designed S protein receptor binding domain (RBD) sequence SEQ ID NO:17, designed truncated S protein sequence SEQ ID NO:15, and designed full length S protein sequence SEQ ID NO:13. Designed coronavirus envelope (E), membrane (M), and nucleocapsid (N) protein sequences are also described, and their use as vaccines. Nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, cells, and their use as vaccines against viruses of the coronavirus family are also described.
    Type: Application
    Filed: April 1, 2021
    Publication date: August 29, 2024
    Inventors: Jonathan Luke HEENEY, Sneha VISHWANATH, George CARNELL, David WELLS, Matteo FERRARI
  • ANTI-NOVEL CORONAVIRUS MONOCLONAL ANTIBODY AND APPLICATION THEREOF
    Publication number: 20230174628
    Abstract: The present invention relates to the fields of immunology and molecular virology, and in particular, to the field of diagnosis, prevention and treatment of a novel coronavirus. Specifically, the present invention relates to an anti-novel coronavirus monoclonal antibody and a composition (for example, a diagnostic agent and a therapeutic agent) containing same. In addition, the present invention also relates to use of the antibody. The antibody of the present invention can be used for diagnosing, preventing and/or treating novel coronavirus infections and/or diseases (for example, novel coronavirus pneumonia) caused by the infections.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 8, 2023
    Inventors: Xiaoliang Sunney XIE, Yunlong CAO, Wenjie SUN, Xu ZHANG
  • CORONAVIRUS VACCINE
    Publication number: 20230270841
    Abstract: The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: August 31, 2023
    Applicant: Imperial College Innovations Limited
    Inventors: Robin Shattock, Paul McKay, Anna Blakney
  • Prefusion coronavirus spike proteins and their use
    Patent number: 11964010
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: April 23, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Method of Treating Coronavirus
    Publication number: 20200179367
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Application
    Filed: February 17, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST CORONAVIRUS
    Publication number: 20230263882
    Abstract: Disclosed herein are CpG-amphiphiles and corona virus antigens (e.g., a coronavirus spike protein, a peptide thereof, or a nucleic acid sequence encoding the same) for use in inducing an immune response in a subject, and methods of administering CpG-amphiphiles and coronavirus antigens (e.g., a coronavirus spike protein, a peptide thereof, a coronavirus nucleocapsid protein, a peptide thereof, or a nucleic acid sequence encoding the same) to induce an immune response in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Martin P. STEINBUCK, Lochana M. SEENAPPA, Peter C. DEMUTH, Christopher M. HAQQ, Lisa MCNEIL
  • Coronavirus Immunogenic Compositions, Methods and Uses Thereof
    Publication number: 20220226465
    Abstract: The present specification discloses broad-spectrum, pan-Coronavirus immunogenic composition including amino acid-based, broad-spectrum, pan-Coronavirus immunogenic compositions and nucleotide-based, broad-spectrum, pan-Coronavirus immunogenic compositions, methods and uses for preventing or treating a Coronavirinae-based infection or pathology as well as methods and uses of creating, maintaining or restoring antigenic memory to one or more Coronavirus species, strains, genotypes, subgenotypes, serotypes or genetic/antigenic lineages in an individual or population of individuals.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 21, 2022
    Applicant: ConserV Bioscience
    Inventors: Olga PLEGUEZUELOS MATEO, Kimbell DUNCAN
  • DEVICES FOR DETECTING ANTIBODIES TO CORONAVIRUS ANTIGENS AND METHODS FOR USING THEM
    Publication number: 20230324402
    Abstract: In alternative embodiments, provided are multiplexed systems, compositions, including products of manufacture such as arrays, microarrays and biochips, and kits, and methods, for detecting presence of a coronavirus in a sample, or to detect a coronavirus, e.g., COVID-19, infection. In alternative embodiments, provided are methods for detecting the presence of a coronavirus infection in an individual. In alternative embodiments, provided are vaccines and methods for using them to prevent, mitigate or lessen to effects of, or treat a coronavirus infection in an individual.
    Type: Application
    Filed: March 23, 2021
    Publication date: October 12, 2023
    Inventors: Phillip L. FELGNER, Saahir KHAN, Algimantas JASINSKAS, Rie NAKAJIMA, Rafael RAMIRO DE ASSIS, Per Niklas HEDDE
  • PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF
    Publication number: 20100304363
    Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo
  • Almitrine for treating the hypoxemia of a coronavirus infection
    Publication number: 20230142073
    Abstract: Hypoxemia is an abnormally low O2 concentration in the blood. It can be lethal. When vital organs don't get enough O2 to operate properly. A coronavirus infection can cause hypoxemia. Wherein this is probably the most common cause of coronavirus associated death. COVID-19 has killed millions of people to date. A method comprising the administration of a therapeutically effective amount of almitrine dimesylate to a subject with a coronavirus infection. To treat/ameliorate/reduce/prevent any coronavirus associated hypoxemia in the subject. Therein increasing the subject's chance of survival.
    Type: Application
    Filed: March 15, 2021
    Publication date: May 11, 2023
    Inventor: Michael David Forrest
  • METHODS OF PREVENTING OR TREATING CORONAVIRUS INFECTION AND REDUCING CORONAVIRUS INFECTION RATE IN VITRO WITH ANTIVIRAL COMPOSITION COMPRISING POLY(3,4-ETHYLENEDIOXYTHIOPHENE):POLY(STYRENE SULFONATE)
    Publication number: 20230321138
    Abstract: The present invention provides methods of preventing or treating coronavirus infection and reducing coronavirus infection rate in vitro with antiviral composition comprising poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS), wherein the PEDOT:PSS is selected from PEDOT:PSS aqueous solutions in various formulas. Specifically, the molar ratio of PEDOT to PSS in the PEDOT:PSS aqueous solution in the antiviral composition may be 1:1.5 to 1:6 and the resistivity of the PEDOT:PSS aqueous solution in the antiviral composition may be 100 ?/sq to 5×107 ?/sq. The antiviral composition is used to inhibit the binding between the spike protein of the coronavirus and the host cells with angiotensin-converting enzyme 2 (ACE2) on surface. The coronavirus may be SARS-CoV-2.
    Type: Application
    Filed: June 14, 2022
    Publication date: October 12, 2023
    Inventor: Ming-Han TSAI
  • ORAL CORONAVIRUS INFECTION VACCINE
    Publication number: 20240091342
    Abstract: Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.
    Type: Application
    Filed: January 25, 2022
    Publication date: March 21, 2024
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Kyoto University
    Inventors: Toshiro SHIRAKAWA, Shunpei UENO, Koichi KITAGAWA, Akihiko KONDO, Masanori KAMEOKA, Takane KATAYAMA
  • Canine Respiratory Coronavirus (Crcv) Spike Protein, Polymerase and Hemagglutinin/Esterase
    Publication number: 20070248616
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Application
    Filed: July 1, 2003
    Publication date: October 25, 2007
    Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
  • ANTI-CORONAVIRUS POLYPEPTIDE AS WELL AS DERIVATIVE AND APPLICATION THEREOF
    Publication number: 20240398893
    Abstract: The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-COV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.
    Type: Application
    Filed: June 27, 2024
    Publication date: December 5, 2024
    Applicants: Institute of Microbiology, Chinese Academy of Sciences, Hybio Pharmaceutical Co., Ltd.
    Inventors: Fu GAO, Shaogui ZENG, Qihui WANG, Yangming TANG, Jiantao CHEN, Lili WU, Anqi ZHENG
Narrow Results

Filter by US Classification